Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Colorectal Neoplasms 476Carcinoma, Hepatocellular 131Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 62Pancreatic Neoplasms 54Liver Neoplasms 44Stomach Neoplasms 37Neoplasms 37Esophageal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Colorectal Cancer Metastatic 19Ovarian Neoplasms 15Gastrointestinal Neoplasms 14Breast Neoplasms 13Biliary Tract Neoplasms 13Adenocarcinoma 11Lung Neoplasms 10Carcinoma, Renal Cell 10Digestive System Neoplasms 9Cholangiocarcinoma 9Intestinal Neoplasms 8Melanoma 7Gallbladder Neoplasms 7Glioblastoma 6Endometrial Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Sarcoma 5Prostatic Neoplasms 5

Interventions

pegfilgrastim 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fever × Bevacizumab × Gastrointestinal × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡